Sugi Predict

Sugi Predict / Targets / BMPR2

BMPR2

Bone morphogenetic protein receptor type-2 · Q13873 · BMPR2 on Sugi Atlas →

8,909 patent compounds predicted against BMPR2, 7,296 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3620876 SCHEMBL3620876 0.56 12/20
SCHEMBL3999294 SCHEMBL3999294 0.48 11/20
SCHEMBL3612317 SCHEMBL3612317 0.55 10/20
SCHEMBL1636291 SCHEMBL1636291 0.51 9/20
SCHEMBL2018504 SCHEMBL2018504 0.45 8/20
SCHEMBL1633112 SCHEMBL1633112 0.54 7/20
SCHEMBL4002054 SCHEMBL4002054 0.52 7/20
SCHEMBL2339372 SCHEMBL2339372 0.48 7/20
SCHEMBL2022312 SCHEMBL2022312 0.41 7/20
SCHEMBL1632131 SCHEMBL1632131 0.52 6/20
SCHEMBL2016134 SCHEMBL2016134 0.43 6/20
SCHEMBL2016137 SCHEMBL2016137 0.43 6/20
SCHEMBL1203750 SCHEMBL1203750 0.51 5/20
SCHEMBL3451149 SCHEMBL3451149 0.44 5/20
SCHEMBL2022343 SCHEMBL2022343 0.43 5/20
SCHEMBL2022344 SCHEMBL2022344 0.43 5/20
SCHEMBL2262093 SCHEMBL2262093 0.37 5/20
SCHEMBL456393 SCHEMBL456393 1.00 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL2059683) 0.98 4/20
SCHEMBL2059688 SCHEMBL2059688 0.77 4/20

Clinical trials — most relevant to BMPR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Vitamin D and Carboxy PTH Fragments in Coronary Calcification PHASE4WITHDRAWN
Socket Augmentation Using Atorvastatin With Or Without PRGF (Clinical and Histomorphometric Study) PHASE4COMPLETED
Socket Augmentation Using Platelet Concentrates, Atorvastatin Gel or Combination PHASE4COMPLETED
The Use of Adhesion Molecule Loaded Hydrogel With Minimally Invasive Surgical Technique in Treatment of Periodontal Intrabony Defect PHASE1/PHASE2COMPLETED
Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat) PHASE2COMPLETED
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor PHASE1/PHASE2COMPLETED
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy PHASE1COMPLETED
Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment PHASE1COMPLETED
Endothelial Cell Dysfunction in Pulmonary Hypertension PHASE1COMPLETED
Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension nanCOMPLETED
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention nanUNKNOWN
Genetic and Environmental Characteristics of Primary Pulmonary Hypertension nanCOMPLETED
StratosPHere (Non-interventional Study) nanCOMPLETED
Short-term Impact of Cyplexinol® on Self-reported Joint Pain nanCOMPLETED
National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension nanUNKNOWN
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers nanCOMPLETED
BMPR2 Mutations and Iron Metabolism in Pulmonary Arterial Hypertension nanCOMPLETED
Induce XT™ Bone Graft in Foot and Ankle Fusion nanENROLLING_BY_INVITATION
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension nanUNKNOWN
Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension nanCOMPLETED
Importance of Neurogenic Inflammation in the Angiogenic Response of the Dental Pulp as a Defensive Response nanCOMPLETED
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH nanWITHDRAWN
Genes-in-Action - Hepcidin Regulation of Iron Supplementation nanCOMPLETED
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals nanRECRUITING
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer nanUNKNOWN
Transcription Factor Runx2 in Necrotic Femoral Head Tissue nanCOMPLETED
Release Kinetics of rhBMP-2 Using E-PRF as an Autologous Carrier: An In Vitro Analysis nanNOT_YET_RECRUITING
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches. nanRECRUITING
Evaluation of the Osteoinductivity of Atorvastatin Combined With β-TCP nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BMPR2 binder may also engage these)

ProteinNameSimilarity
O35607 — 1.000 O35607 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.997 landscape →
Q297L2 — 0.994 Q297L2 →
A7MBB4 — 0.994 A7MBB4 →
Q6NN85 — 0.994 Q6NN85 →
Q5R8X7 — 0.994 Q5R8X7 →
G5EFD2 — 0.994 G5EFD2 →
A8XQD5 — 0.994 A8XQD5 →
Q2PFD7 — 0.993 Q2PFD7 →
B2GUY1 — 0.992 B2GUY1 →
A6QP06 — 0.992 A6QP06 →
Q1HKZ5 — 0.992 Q1HKZ5 →
P46200 — 0.992 P46200 →
Q92539 — 0.992 Q92539 →
BMP2K BMP-2-inducible protein kinase 0.992 landscape →
Q03345 — 0.992 Q03345 →
Q17353 — 0.992 Q17353 →
G5EEC5 — 0.992 G5EEC5 →
Q9NA64 — 0.992 Q9NA64 →
P49844 — 0.991 P49844 →
P06536 — 0.991 P06536 →
Q0WPH8 — 0.991 Q0WPH8 →
Q17AN2 — 0.991 Q17AN2 →
P06537 — 0.991 P06537 →
Q9VFH6 — 0.991 Q9VFH6 →
Q61IS6 — 0.991 Q61IS6 →
A2A3K4 — 0.991 A2A3K4 →
Q6P995 — 0.991 Q6P995 →
Q3YC04 — 0.991 Q3YC04 →
Q08639 — 0.991 Q08639 →